Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 4/20 | 0.58 |
| ▸ | UTS2R | Q9UKP6 | 5/20 | 0.55 |
| ▸ | HTR3A | P46098 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | AHCY | P23526 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5406811 | 0.93 | HTR3A (0.57) | CNR1HTR3AMEN1POLBKMT2A | |
| SCHEMBL5418272 | 0.93 | HTR3A (0.57) | CNR1HTR3AMEN1POLBKMT2A | |
| SCHEMBL5414392 | 0.93 | HTR3A (0.57) | CNR1HTR3AMEN1POLBKMT2A | |
| SCHEMBL5403939 | 0.91 | HTR3A (0.53) | CNR1UTS2RHTR3AMEN1POLB | |
| SCHEMBL5403933 | 0.91 | HTR3A (0.53) | CNR1UTS2RHTR3AMEN1POLB | |
| SCHEMBL5418665 | 0.91 | HTR3A (0.53) | CNR1UTS2RHTR3AMEN1POLB | |
| SCHEMBL5409924 | 0.88 | ALDH1A1 (0.51) | HTR3AMEN1POLBKMT2ASMN1; SMN2 | |
| SCHEMBL5414697 | 0.87 | HTR3A (0.64) | HTR3AMEN1POLBKMT2A | |
| SCHEMBL14543609 | 0.83 | RAB9A (0.50) | CNR1UTS2RHTR3AMEN1POLB | |
| SCHEMBL8295531 | 0.83 | RAB9A (0.50) | CNR1UTS2RHTR3AMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202269-B2 | GlyT2 modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-10 | — | — | US | claimed |
| US-20050119245-A1 | GlyT2 modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-06-02 | — | — | US | claimed |
| US-7202269-B2 | GlyT2 modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-10 | — | — | US | disclosed |
| US-7202269-B2 | GlyT2 modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-10 | — | — | US | disclosed |
| US-7202269-B2 | GlyT2 modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-10 | — | — | US | disclosed |
| US-20050119245-A1 | GlyT2 modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-06-02 | — | — | US | disclosed |
| WO-2005044810-A1 | GLYT2 MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119245-A1 | GlyT2 modulators | GLRB, GLRA1, GLRA2 | CNR1 447/4885UTS2R 855/4885HTR3A 702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.